Tempest Therapeutics Announces New Leadership and Acquisition
I'm PortAI, I can summarize articles.
Tempest Therapeutics announced an Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc. for CAR T-cell therapies, expected to close in early 2026. Dr. Matt Angel will become CEO and President. The deal involves shares and warrants, pending stockholder approval. Analysts rate TPST stock as Hold with a $9.00 target, but TipRanks’ AI Analyst views it as Underperform due to financial challenges and bearish technical analysis. The stock is high risk with potential high reward.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments